• English
  • Français
Bladder Cancer CanadaBladder Cancer CanadaBladder Cancer CanadaBladder Cancer Canada
  • Bladder Cancer
    • See Red?
    • What is Bladder Cancer?
    • Statistics and Risk Factors
    • Symptoms and Diagnosis
    • Staging and Grading
    • Types of Bladder Cancer
      • Non-Muscle Invasive Bladder Cancer
      • Muscle Invasive Bladder Cancer
      • Metastatic Bladder Cancer
      • Upper Tract Urothelial Carcinoma
    • Treatment Options
      • TURBT
      • BCG
      • Chemotherapy and Radiation
      • Bladder Removal
      • Immunotherapy
      • Bladder Preservation Options
      • Palliative Care
      • Clinical Trials
      • Advanced Bladder Cancer Treatment
    • Research and Studies
  • Patients
    • Get Support
      • Support Groups
      • One2One Peer Support
      • Online Discussion Forum
      • Contact Us by Phone or Email
    • Navigating Your Diagnosis
      • Newly Diagnosed?
      • Coping With Emotions
      • Health and Wellness Resources
      • Clinical Trials
    • Educational Resources
      • Guidebooks
      • Webinars and Videos
      • Podcast
      • Newsletter
      • Glossary
    • Upcoming Events
    • News and Stories
    • Links and Other Resources
  • Get Involved
    • Donate
    • Fundraise
    • Volunteer
    • Share Your Story
    • Patient Study Recruitment
    • Patient Self-Advocacy
    • Bladder Cancer Awareness Month
    • Your Impact
  • Health Care Practitioners
    • Doctor Resources
    • BCC Research Grant Applications
    • BCC Research Grant Recipients
    • CBCIS
    • CBCRN
    • Medical Advisory Board
  • About Us
    • Who We Are
    • Board of Directors
    • Staff
    • Medical Advisory Board
    • Sponsors and Partners
    • Financial Statements and Annual Reports
    • Newsletter
    • Contact Us
  • Walk With Us
  • Donate
NextPrevious

BCC Consensus Statement on Integration of TICE and VERITY BCG

By Bladder Cancer Canada | Latest news and stories | 21 December, 2021 | 3

 December 17, 2021 

To:  Physicians Prescribing Treatment for Nonmuscle Invasive Bladder Cancer (NMIBC) 

  • Until 2021, TICE BCG was the only strain available in Canada 
  • A second strain of BCG recently received conditional approval by Health Canada in 2021 and is available in the Canadian market: VERITY-BCG(TM)
  • The past shortage of BCG is therefore resolved. 

The Medical Advisory Board of Bladder Cancer Canada, with endorsement by the Canadian Urological Association (2021), has reviewed and support the following suggestions: 

  • Every patient in need of BCG therapy should receive full dose BCG as per CUA guidelines(1).
    • Patients with high risk NMIBC should receive full dose BCG for 6 weeks of induction and 3 years of maintenance therapy. 
    • When BCG is administered to patients with intermediate risk NMIBC, full dose BCG for 6 weeks of induction and 1 year of maintenance therapy is recommended. 

  • Patients should ideally receive all treatments with a single strain of BCG. However, if supply of one BCG strain is limited, patients should be switched to the other strain if necessary to ensure full dose BCG is administered for the recommended duration of maintenance therapy. 

  • VERITY BCG is not approved by Health Canada for the treatment of CIS and its use should be limited to papillary NMIBC (Ta/T1) without evidence of CIS. Specifically: “Verity-BCG is indicated as an adjuvant therapy after transurethral resection (TUR) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage Ta (grade 2 or 3) or T1 (grade 1, 2, or 3), without concomitant carcinoma in situ. It is only recommended for stage Ta grade 1 papillary tumors, when there is judged to be a high risk (>50%) of tumor recurrence.” 

Sincerely, 

Dr. Peter Black, MD, FRCSC, Chair, BCC Medical Advisory Board 

Dr. Wassim Kassouf, MD, CM, FRCSC, Past Chair, BCC Medical Advisory Board, CUA Treasurer 

Dr. Girish Kulkarni, MD, PHD, FRCSC, Vice Chair, BCC Medical Advisory Board Chair, CUA Continuing Professional Development Committee 

No tags.

Related Post

  • Volunteer’s personal approach leads to deeper commitment from corporate supporter

    By Bladder Cancer Canada | 0 comment

    By: Tom Eremondi Read time: 3.5 minutes Admittedly old school, Gerry Ross’ approach to dealing with a local walk sponsor nurtured and enhanced the relationship to a surprising level. This story, however, dates back aboutRead more

  • “The risk of recurrence of my cancer is high, so I need to take care of myself.”

    By Bladder Cancer Canada | 0 comment

    Read time: 2 minutes We were so pleased to see one of our new Peer Support Volunteers, Gervais  Fournier, featured in this New Normal, Same Cancer news story, seen last month in the Le JournalRead more

  • This May, we’re making bladder cancer impossible to ignore! 

    By Bladder Cancer Canada | Comments are Closed

    Subscribe today! Our May newsletter is filled with lots of initiatives to create awareness for bladder cancer including blogs, podcasts, helpful facts, webinars and more. Bladder cancer is the 5th most common cancer in Canada andRead more

  • Bladder cancer & COVID-19 FAQ

    By Bladder Cancer Canada | Comments are Closed

    Uncertain times are upon us, around the world, as we globally respond to the coronavirus (COVID-19) that is affecting us all on some level. Many members of our bladder cancer community are directing questions our way aboutRead more

  • Protecting Yourself During the Coronavirus Outbreak

    By Bladder Cancer Canada | Comments are Closed

    (The following content is sourced from various sites advising on the coronavirus. For more information, please see the end of this article for additional resources. Photo Credit: CDC) As news of the coronavirus (COVID-19) continues toRead more

  • Health Canada Approves BALVERSA

    By Bladder Cancer Canada | Comments are Closed

    In a recent press release, Janssen Pharmaceutical Companies of Johnson & Johnson have announced that they have received approval from Health Canada for BALVERSA™ (erdafitinib), the first FGFR Kinase inhibitor for the treatment of patientsRead more

  • Our First Annual Research Report Is Live! 

    By Bladder Cancer Canada | Comments are Closed

    Our first Annual Research Report brings you exciting updates from the world of bladder cancer research.

  • Tax Season is Upon Us! 

    By Bladder Cancer Canada | Comments are Closed

    Spring has sprung and so has tax season! Don’t miss out on valuable credits or deductions! 

  • Happy National Volunteer Week 2025!

    By Bladder Cancer Canada | Comments are Closed

    National Volunteer Week is celebrated annually to honour all the volunteers who make a powerful impact.

  • Patient Story: Stéphanie

    By Bladder Cancer Canada | Comments are Closed

    My life turned upside down with the announcement of a bladder cancer diagnosis.

  • Join us for an Education Event in Vancouver this May! 

    By Bladder Cancer Canada | Comments are Closed

    Bladder Cancer Canada is thrilled to be hosting a special education event in Vancouver!

2 comments

  • Antoinette Leclerc Langelier .Leclerc Reply February 27, 2022 at 9:02 am

    j’ai très très mal au coté gauche au bas du ventre. je ne sais ce qui m’arrive
    j’ai mis de la glace j’i pris des adwill. j’ai toujours mal.
    depuis hier après midi 16h00

  • Tawny Barratt Reply February 28, 2022 at 5:31 pm

    Nous sommes désolés d’apprendre que cela se produit. Nous ne sommes pas en mesure de donner des conseils médicaux, veuillez consulter votre médecin pour les soins et le traitement.

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

NextPrevious

Recent Blog Posts

  • Our First Annual Research Report Is Live! 
  • Economic Impacts of a Cancer Diagnosis on Canadians
  • Tax Season is Upon Us! 
  • Happy National Volunteer Week 2025!
  • Movement Matters: Simple Workouts for Bladder Cancer Patients

Upcoming Events

  • Outreach Events
  • In-person Education Events
  • Support Groups
  • Webinars

Blog Categories

  • Blog
  • Honouring our volunteers
  • Latest news and stories
  • Patient Stories
  • Upcoming meeting and events
  • Volunteers
  • Webinar

Bladder Cancer Canada

4936 Yonge Street, Suite 1000, Toronto, ON M2N 6S3
Phone: 1-866-674-8889
Email & Media Contact: info@bladdercancercanada.org

Privacy Policy | Donor Bill of Rights

Charitable Reg No. 83612 6060 RR0001

© Bladder Cancer Canada.

SUBSCRIBE TO OUR NEWSLETTER
SEND US A MESSAGE
  • Bladder Cancer
    • See Red?
    • What is Bladder Cancer?
    • Statistics and Risk Factors
    • Symptoms and Diagnosis
    • Staging and Grading
    • Types of Bladder Cancer
      • Non-Muscle Invasive Bladder Cancer
      • Muscle Invasive Bladder Cancer
      • Metastatic Bladder Cancer
      • Upper Tract Urothelial Carcinoma
    • Treatment Options
      • TURBT
      • BCG
      • Chemotherapy and Radiation
      • Bladder Removal
      • Immunotherapy
      • Bladder Preservation Options
      • Palliative Care
      • Clinical Trials
      • Advanced Bladder Cancer Treatment
    • Research and Studies
  • Patients
    • Get Support
      • Support Groups
      • One2One Peer Support
      • Online Discussion Forum
      • Contact Us by Phone or Email
    • Navigating Your Diagnosis
      • Newly Diagnosed?
      • Coping With Emotions
      • Health and Wellness Resources
      • Clinical Trials
    • Educational Resources
      • Guidebooks
      • Webinars and Videos
      • Podcast
      • Newsletter
      • Glossary
    • Upcoming Events
    • News and Stories
    • Links and Other Resources
  • Get Involved
    • Donate
    • Fundraise
    • Volunteer
    • Share Your Story
    • Patient Study Recruitment
    • Patient Self-Advocacy
    • Bladder Cancer Awareness Month
    • Your Impact
  • Health Care Practitioners
    • Doctor Resources
    • BCC Research Grant Applications
    • BCC Research Grant Recipients
    • CBCIS
    • CBCRN
    • Medical Advisory Board
  • About Us
    • Who We Are
    • Board of Directors
    • Staff
    • Medical Advisory Board
    • Sponsors and Partners
    • Financial Statements and Annual Reports
    • Newsletter
    • Contact Us
  • Walk With Us
  • Donate
Bladder Cancer Canada